Small molecular acid pyrazole curcumin derivative as well as preparation method and application thereof

By modifying the β-dione structure of curcumin into a five-membered pyrazole nitrogen heterocycle and introducing small-molecular acid groups, a small-molecular acid pyrazole curcumin derivative was designed, which solved the problem of low curcumin stability and bioavailability. The problem has improved its anti-tumor activity and clinical application value.

CN118994013AInactive Publication Date: 2024-11-22HEBEI UNIV OF SCI & TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411098626.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Curcumin has poor stability and low bioavailability in clinical applications, which leads to poor effectiveness in treating cancer.

Method used

By transforming the β-dione structure of curcumin into an electron-rich five-membered pyrazole nitrogen heterocycle and introducing small molecule acid groups on the pyrazole nitrogen atom, a small molecule acid pyrazole curcumin derivative is designed to obtain. Improves its drug stability and anti-tumor activity.

Benefits of technology

It significantly improves the blood concentration and bioavailability of the compounds, enhances the targeting of cancer cells, provides new ideas for the development of anti-tumor drugs, and has high clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BSA0000299650260000021
    Figure BSA0000299650260000021
  • Figure BSA0000299650260000023
    Figure BSA0000299650260000023
  • Figure BSA0000299650260000031
    Figure BSA0000299650260000031
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical compounds, and particularly discloses a small molecular acid pyrazole curcumin derivative as well as a preparation method and application thereof. According to the invention, pyrazol curcumin is taken as a mother nucleus, and a small-molecular organic acid group is introduced to a pyrazol nitrogen atom, so that the obtained small-molecular pyrazol curcumin derivative has excellent activity of inhibiting lung cancer cell proliferation in vitro, and can be used for preparing medicines for treating and preventing lung cancer. Meanwhile, the compound is rich in raw material source, low in price, simple in preparation process and convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment scheme for patients with lung cancer, has important significance for breaking through the treatment bottleneck of lung cancer and developing the curcumin into medicines, and has wide potential application fields.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical compounds, and in particular to a small molecule acid pyrazole curcumin derivative and a preparation method and application thereof. Background Art

[0002] Cancer is a malignant disease that endangers human life and health. Most of the commonly used anticancer drugs in clinical practice have serious side effects and certain drug resistance, and the treatment effect is poor. Although new anticancer drugs have been rapidly developed in recent years, the search for highly effective and low-toxic anticancer drugs is still a research hotspot in the field of tumor treatment.

[0003] Curcumin is a polyphenolic medicinal plant with multiple pharmacological activities, and is listed as a third-generation anticancer chemopreventive drug by the National Cancer Institute of the United States. Studies have shown that curcumin is expected to become an efficient and low-toxic anticancer drug with potential clinical application value. However, the β-diketone structure in the curcumin structure leads to its poor stability and low bioavailability, which limits the clinical application of curcumin. In order to break the above bottleneck, pyrazole curcumin is used as the lead compound, and small molecule organic acid compounds with good pharmacological activity and biocompatibility are introduced through structural modification and transformation. Pyrazole curcumin derivatives with novel structure and good antitumor activity are designed, which is of great significance to realize the clinical application value of curcumin. Cancer is a malignant disease caused by the loss of normal regulation and excessive proliferation of body cells. It has become a major killer that endangers human life and health. At present, cancer treatment is still an arduous task. Most of the chemotherapy drugs commonly used in clinical practice have the disadvantages of low efficacy on solid tumors, large toxic side effects, and easy to produce drug resistance. Therefore, the development of low-toxic and efficient anti-tumor drugs is still one of the important research directions of today's medical research and development. Summary of the invention

[0004] In view of the technical problems that curcumin is unstable under physiological conditions in vivo and has low bioavailability when currently used clinically, the present invention provides a small molecule acid pyrazole curcumin derivative and a preparation method and application thereof.

[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:

[0006] In a first aspect, the present invention provides a small molecule acid pyrazole curcumin derivative, the structure of which is shown in formula (I):

[0007]

[0008] Among them, R is

[0009] Studies have confirmed that β-diketone is the key factor that causes curcumin to be unstable under physiological conditions, and experiments have confirmed that its stability can be effectively improved by modifying the diketone structure.

[0010] Based on this, the inventors transformed the β-diketone structure of curcumin into an electron-rich five-membered pyrazole nitrogen heterocycle, and designed a new compound with pyrazole curcumin as the parent core and introduced a specific small molecule acid group on its pyrazole nitrogen atom. The drug stability of this compound is significantly improved, and it also has excellent anti-tumor activity, which provides new ideas for the development and utilization of new anti-tumor drugs and curcumin, and has high potential application value.

[0011] Specifically, the structure of the small molecule acid pyrazole curcumin derivative is as follows:

[0012]

[0013] Further preferably, the structure of the small molecule acid pyrazole curcumin derivative is as follows:

[0014]

[0015] The present invention effectively increases the blood drug concentration and bioavailability of the modified compound by structurally modifying the nitrogen atom of pyrazole curcumin. At the same time, the above preferred compound has the targeting property of binding to cancer cells, can improve the killing property to tumor cells, and has high clinical application value.

[0016] In a second aspect, the present invention also provides a method for preparing the above-mentioned small molecule acid pyrazole curcumin derivatives, comprising the following steps:

[0017] Using curcumin as a raw material, a pyrazole curcumin represented by formula (II) is obtained through a cyclization reaction;

[0018] Using the compound of formula (II) as the raw material, after a substitution reaction and protecting the hydroxyl group, a compound of formula (III) is obtained;

[0019] The compound represented by formula (III) is subjected to an acid-amine condensation reaction with a small molecule organic acid compound, and then deprotected to obtain a small molecule acid pyrazole curcumin derivative represented by formula (I);

[0020]

[0021] Wherein, the small molecule organic acid compound is trans-cinnamic acid, ferulic acid, nicotinic acid, D-biotin, α-lipoic acid, p-toluenesulfonic acid or methanesulfonic acid.

[0022] Compared with the prior art, the preparation method of the small molecule acid pyrazole curcumin derivatives provided by the present invention has short synthesis steps, simple operation, mild reaction conditions, high purity of the obtained product, good industrial utilization value, and high promotion and application value.

[0023] Furthermore, the preparation method of the small molecule acid pyrazole curcumin derivatives specifically comprises the following steps:

[0024] S1. Dissolve curcumin in glacial acetic acid, add hydrazine hydrate, carry out cyclization reaction, and monitor by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (II);

[0025] S2, adding the compound represented by formula (II) and an organic base into an organic solvent a, mixing evenly, adding TBS hydroxyl protective agent, and monitoring by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (III);

[0026] S3, adding a small molecule acid compound, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole to an organic solvent b, stirring for activation, adding a compound represented by formula (III), carrying out an acid-amine condensation reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (IV);

[0027]

[0028] Among them, R is

[0029] S4, dissolving the compound represented by formula (IV) in an organic solvent c, adding glacial acetic acid, adding fluoride, carrying out a deprotection reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain a small molecule acid pyrazole curcumin derivative represented by formula (I). The specific synthesis route is as follows:

[0030]

[0031] Specifically, the structural formula of R is as follows:

[0032]

[0033] Specifically, the structural formula of the above small molecule acid compound is shown in Table 1:

[0034] Table 1 Structural formula of small molecule organic acid compounds

[0035]

[0036]

[0037] Furthermore, in S1, the molar ratio of curcumin to hydrazine hydrate is 1:(1-10).

[0038] Furthermore, in S1, the molar volume ratio of curcumin to glacial acetic acid is 1 mmol: (1-10) mL.

[0039] Furthermore, in S1, the temperature of the cyclization reaction is (90-120)°C.

[0040] Furthermore, after the reaction of S1 is completed, a post-treatment process is also included: the reaction solution is evaporated under reduced pressure to dry the solvent, the obtained crude product is dissolved in an organic solvent, and then washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, the filtrate is concentrated under reduced pressure, and purified by pulping with an alcohol solvent to obtain the pyrazole curcumin shown in formula (II).

[0041] Specifically, in S1, during the post-treatment process, the organic solvent is dichloromethane, ethyl acetate or diethyl ether, and the alcohol solvent is methanol, ethanol or isopropanol.

[0042] Furthermore, in S2, the molar ratio of the organic base, the TBS hydroxyl protecting agent and the compound represented by formula (II) is (1-10):(1-10):1.

[0043] Furthermore, in S2, the volume molar ratio of the organic solvent a to the compound represented by formula (II) is (0.2-2) mL:1 mmol.

[0044] Furthermore, in S2, the reaction temperature is (20-40)°C.

[0045] Furthermore, in S2, the organic solvent a is at least one of N,N-dimethylformamide, dimethyl sulfoxide or toluene.

[0046] Furthermore, in S2, the organic base is at least one of imidazole, pyridine or triethylamine.

[0047] Furthermore, in S2, the TBS hydroxyl protecting agent is tert-butyldimethylsilyl chloride or tert-butyldimethylsilyl trifluoromethanesulfonate.

[0048] Furthermore, after the reaction of S2 is completed, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, and then washing with pure water, saturated sodium bicarbonate solution and saturated saline solution in sequence, drying with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and purifying with an alcohol solvent to obtain a hydroxyl-protected pyrazole curcumin shown in formula (III).

[0049] Specifically, in S2, during the post-treatment process, the organic solvent is dichloromethane, ethyl acetate or diethyl ether, and the alcohol solvent is methanol, ethanol or isopropanol.

[0050] Furthermore, in S3, the molar ratio of the small molecule acid compound, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole and the compound represented by formula (III) is (1-10):(1-10):(1-10):1.

[0051] Furthermore, in S3, the organic solvent b is at least one of anhydrous dichloromethane, N,N-dimethylformamide or dimethyl sulfoxide.

[0052] Furthermore, in S3, the volume molar ratio of the organic solvent b to the compound represented by formula (III) is (5-50) mL:1 mmol.

[0053] Furthermore, in S3, the temperature of the acid-amine condensation reaction is (20-40)°C.

[0054] Furthermore, after the completion of the S3 reaction, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, and then washing with water, a saturated sodium bicarbonate solution and a saturated saline solution in sequence, drying over anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain a compound represented by formula (IV).

[0055] Specifically, in S3, during the post-treatment process, the organic solvent is dichloromethane, ethyl acetate or diethyl ether, and the eluent of the silica gel column chromatography is petroleum ether / ethyl acetate or dichloromethane / methanol.

[0056] Furthermore, in S4, the volume molar ratio of the glacial acetic acid, the fluoride and the compound represented by formula (IV) is (0.02-0.2) mL: (0.5-5) mL: 1 mmol.

[0057] Furthermore, in S4, the organic solvent c is anhydrous tetrahydrofuran.

[0058] Furthermore, in S4, the fluoride is one or both of tetrabutylammonium fluoride and pyridine hydrogen fluoride complex.

[0059] Furthermore, in S4, the volume molar ratio of the organic solvent c to the compound represented by formula (IV) is (10-50) mL:1 mmol.

[0060] Furthermore, in S4, the temperature of the deprotection reaction is (-10 to 10)°C.

[0061] Furthermore, after the reaction S4 is completed, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, and then washing with water, a saturated sodium bicarbonate solution and a saturated saline solution in sequence, drying over anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain a compound represented by formula (I).

[0062] Specifically, in the post-treatment process in S4, the organic solvent is dichloromethane, ethyl acetate or diethyl ether, and the eluent of the silica gel column chromatography is petroleum ether / ethyl acetate or dichloromethane / methanol.

[0063] The above-mentioned preferred reaction conditions are conducive to improving the yield and purity of the products in each step.

[0064] The present invention also provides the use of the small molecule acid pyrazole curcumin derivatives in the preparation of anti-lung cancer drugs.

[0065] The small molecule acid pyrazole curcumin derivatives provided by the present invention have significant in vitro activity of inhibiting lung cancer cell proliferation, and are conducive to improving blood drug concentration and enhancing the targeting of binding to cancer cells to improve its bioavailability, and can be used to prepare drugs for treating and preventing lung cancer. At the same time, the raw material sources of the compound are abundant, the price is low, the preparation process is simple, and it is convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment plan for lung cancer patients, which is of great significance to breaking through the treatment bottleneck of lung cancer and the development of curcumin as a drug, and has a wide potential application field. DETAILED DESCRIPTION

[0066] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0067] The embodiment of the present invention provides a method for preparing a small molecule acid pyrazole curcumin derivative, comprising the following steps:

[0068] Curcumin (Formula 1) is used as a raw material, and a pyrazole curcumin shown in Formula 2 is obtained through a cyclization reaction;

[0069] Using formula 2 as the raw material, after a substitution reaction and protecting the hydroxyl group, a compound shown in formula 3 is obtained;

[0070] The compound represented by Formula 3 is subjected to an acid-amine condensation reaction with a small molecule organic acid compound (Formula 4 to Formula 10) to obtain compounds represented by Formula 11 to Formula 17;

[0071] The compounds represented by Formula 11 to Formula 17 are deprotected from hydroxyl groups to obtain small molecular weight acid pyrazole curcumin derivatives represented by Formula 18 to Formula 24. The specific reaction route is as follows:

[0072]

[0073] In order to better illustrate the present invention, further examples are given below.

[0074] Example 1

[0075] Synthesis of the compound represented by formula 2

[0076] At room temperature, hydrazine hydrate (2.80 g, 55.81 mmol) was slowly dripped into a solution of curcumin (10.00 g, 27.10 mmol) in glacial acetic acid (100 mL). After the addition was completed, the temperature was stirred and raised to 110 ° C. During the period, the reaction solution changed from an orange-yellow suspension to a reddish brown clarification. The reaction progress was monitored by TLC thin-layer chromatography. The reaction was stopped after 8 h, and the solvent was evaporated to dryness. The crude product was dissolved in 50 mL of ethyl acetate, and the organic phase was washed with water (15 mL) and saturated brine (15 mL) in turn. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Anhydrous ethanol (20 mL) was added for pulping and purification, and filtered. The filter cake was dried to obtain the compound shown in Formula 2 as a light yellow solid, 5.50 g, and the yield was 55.0%.

[0077] Structural Elucidation Data:

[0078] mp=(212.7-215.1)℃.

[0079] 1 H NMR (500MHz, DMSO-d6): δ 12.78 (s, 1H), 9.16 (s, 2H), 7.14 (s, 2H), 7.04 (m, 2H), 6.94-6.90 (m, 4H), 6.77 (m, 2H), 6.58 (s, 1H), 3.83 (s, 6H).

[0080] LC-MS (ESI, m / z) Calcd for: C 21 H 21 N2O4[M+H] + :365.1, found:365.1.

[0081] Example 2

[0082] Synthesis of the compound represented by formula 3

[0083] At room temperature, the compound shown in formula 2 (8.00 g, 22.0 mmol) was added to a 100 mL flask, and imidazole (3.74 g, 54.9 mmol) and N, N-dimethylformamide (16 mL) were added thereto. After stirring for 30 min, TBDMS-Cl (8.25 g, 54.9 mmol) was added, and the reaction progress was monitored by TLC thin layer chromatography. After reacting at room temperature for 5 h, 10 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×30 mL). The organic phases were combined and washed with pure water (30 mL), saturated sodium bicarbonate aqueous solution (30 mL) and saturated brine (30 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by slurrying with anhydrous ethanol (16 mL), filtered, and the filter cake was dried to obtain the compound shown in formula 3, a white solid powder, 12.01 g, and a yield of 92.2%.

[0084] Structural Elucidation Data:

[0085] mp=(219.3-223.1)℃;

[0086] 1 H NMR (500MHz, DMSO-d6) δ12.94 (s, 1H), 7.26-7.06 (m, 5H), 7.03-6.95 (m, 3H), 6.83 (dd, J=17.5, 8.0Hz , 2H), 6.69(s, 1H), 3.84(s, 6H, 2×Ar-OCH3), 0.98(s, 18H, 2×SiC(CH3)3), 0.15(s, 12H, 2×Si(CH3)2).

[0087] LC-MS (ESI, m / z) Calcd for: C 33 H 49 N2O4Si2[M+H] + :593.3, found:593.4.

[0088] Example 3

[0089] Synthesis of the compound represented by formula 18

[0090] Under ice-water bath, the compound represented by formula 4 (0.08 g, 0.56 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.11 g, 0.56 mmol), 1-hydroxybenzotriazole (HOBT) (0.08 g, 0.56 mmol) and anhydrous dichloromethane (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound represented by formula 3 (0.30 g, 0.50 mmol) was added. The reaction mixture was monitored by TLC thin-layer chromatography. The reaction progress was measured. After reacting at room temperature for 24 h, 10 mL of pure water was added to quench the reaction. The organic layer was separated, and the aqueous phase was extracted with dichloromethane (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 20: 1 to 10: 1, v / v) to obtain the compound shown in formula 11, 0.18 g, and the yield was 50.0%.

[0091] Anhydrous tetrahydrofuran (5 mL) and glacial acetic acid (0.02 mL) were added to a flask containing the compound of Formula 11 (0.15 g, 0.21 mmol) in sequence. The reaction mixture was placed in an ice bath and 0.42 mL of m L tetrabutylammonium fluoride (TBAF), after the addition, keep warm and stir in an ice-water bath for 30 minutes, add 10 mL of pure water to quench the reaction, extract with ethyl acetate (3×10 mL), combine the organic phases, wash with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, collect the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The crude product is purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 3: 1 to 2: 1, v / v) to obtain the compound shown in formula 18, orange-yellow solid powder, 0.10 g, yield 78.9%, purity 98.83%.

[0092] Structural Elucidation Data:

[0093] mp=(205.5-207.2)℃;

[0094] 1H NMR (500MHz, DMSO-d6) δ9.40 (s, 1H), 9.32 (s, 1H), 7.96 (s, 2H), 7.81-7.77 (m, 3H), 7.52 (d, J=5.7Hz, 3H), 7.37- 7.27 (m, 4H), 7.16-7.03 (m, 2H), 7.04 (d, J = 8.1Hz, 2H), 6.85 (dd, J = 14.0, 8.1Hz, 2H), 3.88 (s, 3H), 3.87 (s, 3H).

[0095] 13 C NMR (126MHz, DMSO-d6) δ165.66, 154.02, 148.48, 148.43, 148.22, 148.03, 146.61, 146.57, 135.25, 134.73, 132.01, 131.58, 129 .66, 129.20, 128.27, 121.59, 121.25, 118.39, 116.71, 116.31, 116.05, 114.39, 110.54, 110.17, 109.03, 104.89, 56.11, 56.06.

[0096] LC-MS (ESI, m / z) Calcd for: C 30 H 27 N2O5[M+H] + :495.1, found:495.1.

[0097] Synthesis of the compound represented by formula 19

[0098] Under ice-water bath, the compound represented by formula 5 (0.16 g, 0.84 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.18 g, 0.93 mmol), 1-hydroxybenzotriazole (HOBT) (0.13 g, 0.93 mmol) and N,N-dimethylformamide (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed and the compound represented by formula 3 (0.50 g, 0.84 mmol) was added. The reaction progress was monitored by thin layer chromatography. After reacting at room temperature for 24 h, 20 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated aqueous sodium bicarbonate solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 20:1 to 10:1, v / v) to obtain the compound of formula 12, 0.32 g, with a yield of 49.8%.

[0099] Anhydrous tetrahydrofuran (10 mL) and glacial acetic acid (0.04 mL) were added to a flask containing the compound of formula 12 (0.30 g, 0.34 mmol) in sequence, and the reaction was placed in an ice bath. 0.77 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise. After the addition was completed, the mixture was stirred for 30 min in an ice-water bath, and then 10 mL of pure water was added to quench the reaction. The mixture was extracted with ethyl acetate (3×10 mL), and the organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 80: 1 to 50: 1, v / v) to obtain the compound of formula 19, a yellow viscous liquid, 0.19 g, a yield of 70.9%, and a purity of 98.88%.

[0100] Structural Elucidation Data:

[0101] 1 H NMR (500MHz, DMSO-d6) δ9.83 (s, 1H), 9.38 (s, 1H), 9.31 (s, 1H), 7.88 (d, J = 15.8Hz, 1 H), 7.76 (d, J = 3.2Hz, 1H), 7.39 (s, 1H), 7.32 (d, J = 2.0Hz, 2H), 7.30 (d, J = 1.8Hz, 2H) , 7.29 (d, J=2.9Hz, 1H), 7.15 (d, J=1.6Hz, 1H), 7.03 (dd, J=8.1, 1.5Hz, 3H), 6.90 (d, J=8.2Hz, 1H), 6.84 (dd, J=14.0, 8.1Hz, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H).

[0102] 13 C NMR (151MHz, DMSO-d6) δ188.38, 188.31, 188.24, 188.18, 130.12, 130.06, 129.99, 129.92, 129.85, 128.38, 128.31, 128.24, 121.97, 121 .94, 121.85, 100.06, 99.99, 99.92, 78.20, 78.13, 78.04, 78.01, 71.74, 71.67, 71.60, 70.12, 70.06, 69.99, 69.92, 69.86, 68.38, 68.31.

[0103] LC-MS (ESI, m / z) Calcd for: C 31 H28 N2O6Na[M+Na] + :563.1, found:563.3.

[0104] Synthesis of the compound represented by formula 20

[0105] Under ice-water bath, the compound represented by formula 6 (0.11 g, 0.93 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.18 g, 0.93 mmol), 1-hydroxybenzotriazole (HOBT) (0.13 g, 0.93 mmol) and anhydrous dichloromethane (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound represented by formula 3 (0.51 g, 0.84 mmol) was added. The reaction mixture was monitored by TLC thin-layer chromatography. The reaction progress was measured. After reacting at room temperature for 24 h, 10 mL of pure water was added to quench the reaction. The organic layer was separated, and the aqueous phase was extracted with dichloromethane (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15: 1 to 10: 1, v / v) to obtain the compound shown in formula 13, 0.32 g, and a yield of 55.3%.

[0106] Anhydrous tetrahydrofuran (10 mL) and glacial acetic acid (0.04 mL) were added to a flask containing the compound of formula 13 (0.23 g, 0.33 mmol) in sequence, the reaction was placed in an ice bath, 0.69 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise, 10 mL of pure water was added to quench the reaction, and ethyl acetate (3×10 mL) was used for extraction. The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 1.5: 1 to 1: 1, v / v) to obtain the compound of formula 20 as a yellow solid powder, 0.13 g, with a yield of 80.6% and a purity of 98.54%.

[0107] Structural Elucidation Data:

[0108] mp=(174.1-176.0)℃;

[0109] 1H NMR (500MHz, DMSO-d6) δ9.42 (s, 1H), 9.31 (s, 1H), 9.08 (s, 1H), 8.83 (d, J = 3.5Hz, 1H), 8.32 (d, J = 8.0Hz, 1H), 7.64-7.61 (m, 2H), 7.44 (s, 1 H), 7.33 (dd, J=19.8, 17.5Hz, 4H), 7.17 (s, 1H), 7.07-7.04 (m, 3H), 6.86 (d, J=8.1Hz, 1H), 6.80 (d, J=8.1Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H).

[0110] 13 C NMR (151MHz, DMSO-d6) δ188.38, 188.31, 188.24, 130.12, 130.05, 129.98, 129.91, 129.85, 128.40, 128.33, 128.26, 1 21.95, 121.94, 100.06, 99.99, 99.92, 78.04, 71.72, 71.65, 71.58, 70.13, 70.07, 70.00, 69.93, 69.93, 69.86, 68.34.

[0111] LC-MS (ESI, m / z) Calcd for: C 27 H 24 N3O5[M+H] + :470.1,found:470.1.

[0112] Synthesis of the compound represented by formula 21

[0113] Under ice-water bath, the compound represented by formula 7 (0.14 g, 0.56 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.11 g, 0.56 mmol), 1-hydroxybenzotriazole (HOBT) (0.08 g, 0.56 mmol) and dimethyl sulfoxide (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound represented by formula 3 (0.31 g, 0.51 mmol) was added. Thin layer chromatography was performed. The reaction progress was monitored by spectrophotometer. After reacting at room temperature for 24 h, 20 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated aqueous sodium bicarbonate solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 100: 1 to 50: 1, v / v) to obtain the compound of formula 14, 0.14 g, with a yield of 35.3%.

[0114] Anhydrous tetrahydrofuran (10 ml) and glacial acetic acid (0.01 mL) were added to a flask containing the compound of formula 14 (0.10 g, 0.33 mmol) in sequence. The reaction was placed in an ice bath, and 0.26 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise. After the addition was completed, 10 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: dichloromethane: methanol = 50: 1 to 30: 1, v / v) to obtain the compound of formula 21 as a yellow solid powder, 0.05 g, with a yield of 74.3% and a purity of 98.67%.

[0115] Structural Elucidation Data:

[0116] mp=(133.3-135.1)℃;

[0117] 1H NMR (500MHz, DMSO-d6) δ9.37 (s, 1H), 9.29 (s, 1H), 7.67 (d, J=16.4Hz, 1H), 7.28 (dd, J=15.5, 5.6H z, 3H), 7.12 (s, 1H), 7.07-7.01 (m, 2H), 6.83 (dd, J=13.6, 8.1Hz, 2H), 6.49 (s, 1H), 6.38 (s, 1H), 4 .34-4.32(m, 1H), 4.18-4.16(m, 1H), 3.86(s, 3H), 3.85(s, 3H), 3.60(s, 1H), 3.15(d, J=6.8Hz, 2H ), 2.85 (dd, J=12.4, 5.0Hz, 1H), 2.61 (d, J=12.4Hz, 1H), 1.72 (d, J=7.1Hz, 2H), 1.59-1.40 (m, 4H).

[0118] 13 C NMR (126MHz, DMSO-d6) δ173.80, 163.30, 153.80, 148.45, 148.37, 148.17, 147.95 , 146.12, 134.95, 134.77, 128.83, 128.27, 128.25, 121.50, 121.14, 120.55, 116. 79, 116.30, 116.10, 116.04, 114.36, 110.64, 110.18, 109.98, 104.30, 99.81, 61.58, 61.56, 59.74, 59.72, 55.94, 55.86, 51.67, 49.11, 33.59, 28.53, 24.99, 24.42.

[0119] LC-MS (ESI, m / z) Calcd for: C 31 H 34 N4O6SNa[M+Na] + :613.2, found:613.3.

[0120] Synthesis of the compound represented by formula 22

[0121] Under ice-water bath, the compound shown in formula 8 (0.29 g, 1.42 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.29 g, 1.53 mmol), 1-hydroxybenzotriazole (HOBT) (0.20 g, 1.53 mmol) and anhydrous dichloromethane (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound shown in formula 3 (0.70 g, 1.18 mmol) was added, and the reaction mixture was monitored by thin layer chromatography. Reaction process: After reacting at room temperature for 24 hours, 10 mL of pure water was added to quench the reaction, the organic layer was separated, the aqueous phase was extracted with dichloromethane (3×10 mL), the organic phases were combined, washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15: 1 to 10: 1, v / v) to obtain the compound shown in formula 15, 0.61 g, and the yield was 67.2%.

[0122] Anhydrous tetrahydrofuran (15 mL) and glacial acetic acid (0.1 mL) were added to a flask containing the compound shown in Formula 15 (0.60 g, 0.77 mmol) in sequence. The reaction was placed in an ice bath, and 1.66 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise. After the addition, 10 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated aqueous sodium bicarbonate solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 5:1 to 2:1, v / v) to obtain the compound shown in Formula 22, a yellow viscous liquid, 0.35 g, a yield of 80.0%, and a purity of 98.78%.

[0123] Structural Elucidation Data:

[0124] 1 H NMR (500MHz, DMSO-d6) δ9.38 (s, 1H), 9.29 (s, 1H), 7.67 (d, J=16.3Hz, 1H), 7.30-7.26 (m, 4H), 7.12 (d, J=1.9Hz, 1H), 7.03-7.01 (m, 3H), 6.85-6.80 ( m, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.24-3.19 (m, 1H), 3.17-3.13 (m, 4H), 2. 46-2.43(m, 1H), 1.93-1.89(m, 1H), 1.74-1.71(m, 4H), 1.51-1.48(m, 2H).

[0125] 13 C NMR (126MHz, DMSO-d6) δ174.51, 153.80, 148.46, 148.39, 148.18, 147.96, 146.12, 134.99, 134.81, 128.25, 128.23, 121.51, 121.13, 116.77, 116.30, 116.03, 114.33, 110.66, 110.19, 104.34, 56.60, 56.12, 56.09, 38.64, 35.37, 34.67, 28.65, 24.20.

[0126] LC-MS (ESI, m / z) Calcd for: C 29 H 32 N2O5S2Na[M+Na] + :575.1, found:575.1.

[0127] Synthesis of the compound represented by formula 23

[0128] Under ice-water bath, the compound shown in formula 9 (0.07 g, 0.37 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.07 g, 0.37 mmol), 1-hydroxybenzotriazole (HOBT) (0.05 g, 0.37 mmol) and anhydrous dichloromethane (8 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound shown in formula 3 (0.20 g, 0.33 mmol) was added, and the reaction was monitored by thin layer chromatography. Process, after reacting at room temperature for 24 hours, 10 mL of pure water was added thereto to quench the reaction, the organic layer was separated, the aqueous phase was extracted with dichloromethane (3×10 mL), the organic phases were combined, washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15: 1 to 8: 1, v / v) to obtain the compound shown in formula 16, 0.19 g, and the yield was 47.1%.

[0129] To a flask containing the compound of formula 16 (0.11 g, 0.15 mmol), anhydrous tetrahydrofuran (5 mL) and glacial acetic acid (0.02 mL) were added in sequence, the reaction was placed in an ice bath, 0.30 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise, 10 mL of pure water was added to quench the reaction, and ethyl acetate (3×10 mL) was used for extraction. The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 3:1, v / v) to obtain the compound of formula 23, a light yellow viscous liquid, 0.06 g, a yield of 73.6%, and a purity of 98.61%.

[0130] Structural Elucidation Data:

[0131] 1 H NMR (500MHz, DMSO-d6) δ9.46 (s, 1H), 9.31 (s, 1H), 7.83-7.81 (m, 2H), 7.48-7.42 (m, 3H), 7.27-7.19 (m, 4H), 7.15 (s, 1H), 7. 09 (d, J=8.1Hz, 1H), 7.00-6.96 (m, 2H), 6.87 (d, J=8.1Hz, 1H), 6.79 (d, J=8.1Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.38 (s, 3H).

[0132] LC-MS (ESI, m / z) Calcd for: C 28 H 27 N2O6S[M+H] + :519.1,found:519.1.

[0133] Synthesis of the compound represented by formula 24

[0134] Under ice-water bath, the compound represented by formula 10 (0.06 g, 0.55 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.11 g, 0.56 mmol), 1-hydroxybenzotriazole (HOBT) (0.08 g, 0.56 mmol) and dimethyl sulfoxide (10 mL) were added to a 50 mL single-necked flask in sequence. After stirring and activating in an ice-water bath for 1 h, the ice bath was removed, and the compound represented by formula 3 (0.31 g, 0.51 mmol) was added. Thin layer The reaction progress was monitored by chromatography. After reacting at room temperature for 24 h, 20 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated aqueous sodium bicarbonate solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15: 1 to 8: 1, v / v) to obtain the compound of formula 17, 0.16 g, with a yield of 50.1%.

[0135] Anhydrous tetrahydrofuran (6 ml) and glacial acetic acid (0.03 mL) were added to a flask containing the compound of formula 17 (0.15 g, 0.22 mmol) in sequence. The reaction was placed in an ice bath, and 0.46 mL of tetrabutylammonium fluoride (TBAF) was slowly added dropwise. After the addition was complete, 10 mL of pure water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with pure water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 20: 1 to 10: 1, v / v) to obtain the compound of formula 24 as a white solid powder, 0.08 g, with a yield of 81.9% and a purity of 98.97%.

[0136] Structural Elucidation Data:

[0137] 1 H NMR (500MHz, DMSO-d6) δ9.43 (s, 1H), 9.31 (s, 1H), 7.32-7.25 (m, 5H), 7.13-7.12 (m, 1H), 7.07-7 .02 (m, 3H), 6.85 (d, J = 8.1Hz, 1H), 6.81 (d, J = 8.1Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.55 (s, 3H).

[0138] LC-MS (ESI, m / z) Calcd for: C 22 H 23 N2O6S[M+H] +:441.1, found:441.1.

[0139] The structural formula of the small molecule acid pyrazole curcumin derivatives prepared in this example is shown in Table 2:

[0140] Table 2 Structural formulas of target compounds 18 to 24

[0141]

[0142]

[0143] The reaction raw materials and the addition amount of each reaction raw material in the above examples can adopt other reaction conditions specified in the present invention. As long as they are within the range specified in the present invention, compounds 18 to 24 with higher purity can be prepared.

[0144] Example 4

[0145] In vitro antitumor activity test

[0146] The CCK-8 method was used to determine the proliferation inhibitory activity of the target compounds (compounds represented by Formula 18 to Formula 24) on human non-small cell lung cancer cells A549.

[0147] Human non-small cell lung cancer cells A549 frozen in the logarithmic growth period were placed in a 37°C water bath and shaken to thaw. After the cancer cells were revived, they were pipetted into a centrifuge tube with a 3 mL pipette and centrifuged. The supernatant was added to 1 mL of MEM medium (containing NEAA) and A549 cells were cultured at a rate of 1 × 10 5 / well were inoculated into a 96-well plate and cultured in a constant temperature incubator (5% CO2, 37°C) overnight, the original culture medium was removed, and different concentrations (0 μM / L, 0.001 μM / L, 0.01 μM / L, 0.1 μM / L, 1 μM / L, 4 μM / L, 8 μM / L, 16 μM / L, 32 μM / L and 64 μM / L) of the target compound, curcumin and positive control drug doxorubicin were added, and the 96-well plate after drug addition was placed in a constant temperature incubator for culture for 24 hours, and then CCK-8 reagent (10 μL per well) was added, and the 96-well plate was continued to be incubated in the incubator for 4 hours. After the incubation, the absorbance OD was measured at 450 nm using a microplate reader.

[0148] The cell inhibition rate was calculated by the following formula:

[0149] Cell inhibition rate (%) = 1-(OD treatment / OD blank control) × 100%, anti-tumor data analysis was performed using GraphPad Prism software to calculate the cell half inhibitory concentration (IC 50 ). The results are shown in Table 3.

[0150] Table 3 IC of compounds represented by formula 18 to formula 24 on A549 cells 50 value

[0151]

[0152]

[0153] The experimental results show that the compounds represented by formulas 18, 19, 20, 21 and 24 all exhibited good inhibitory effects on A549 cells, and the inhibitory activities were better than curcumin; the inhibitory activities of the compounds represented by formulas 19, 20 and 21 on A549 were comparable to those of the positive control drug doxorubicin; the anticancer activities of the compounds represented by formulas 22 and 23 were relatively weak.

[0154] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A small molecule acid pyrazole curcumin derivative, characterized in that: Its structure is shown in formula (I): Among them, R is 2. The small molecule acid pyrazole curcumin derivative according to claim 1, characterized in that: R is 3. A small molecule acid pyrazole curcumin derivative according to claim 1 or 2, characterized in that: The steps include: Using curcumin as a raw material, a pyrazole curcumin represented by formula (II) is obtained through a cyclization reaction; Using the compound of formula (II) as the raw material, after a substitution reaction and protecting the hydroxyl group, a compound of formula (III) is obtained; The compound represented by formula (III) is subjected to an acid-amine condensation reaction with a small molecule organic acid compound, and then deprotected to obtain a small molecule acid pyrazole curcumin derivative represented by formula (I); Wherein, the small molecule organic acid compound is trans-cinnamic acid, ferulic acid, nicotinic acid, D-biotin, α-lipoic acid, p-toluenesulfonic acid or methanesulfonic acid.

4. The method for preparing the small molecule acid pyrazole curcumin derivatives as claimed in claim 3, characterized in that: The specific steps include: S1. Dissolve curcumin in glacial acetic acid, add hydrazine hydrate, carry out cyclization reaction, and monitor by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (II); S2, adding the compound represented by formula (II) and an organic base into an organic solvent a, mixing evenly, adding TBS hydroxyl protective agent, and monitoring by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (III); S3, adding a small molecule acid compound, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole to an organic solvent b, stirring for activation, adding a compound represented by formula (III), carrying out an acid-amine condensation reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain a compound represented by formula (IV); Among them, R is S4. Dissolve the compound represented by formula (IV) in an organic solvent c, add glacial acetic acid and fluoride, carry out a deprotection reaction, and monitor the reaction by thin layer chromatography until the reaction is completed to obtain a small molecule acid pyrazole curcumin derivative represented by formula (I).

5. The method for preparing the small molecule acid pyrazole curcumin derivatives as claimed in claim 4, characterized in that: In S1, the molar ratio of curcumin to hydrazine hydrate is 1:(1-10); and / or In S1, the molar volume ratio of curcumin to glacial acetic acid is 1 mmoL: (1-10) mL; and / or In S1, the temperature of the cyclization reaction is (90-120)°C.

6. The method for preparing the small molecule acid pyrazole curcumin derivatives according to claim 4, characterized in that: In S2, the molar ratio of the organic base, the TBS hydroxyl protecting agent and the compound represented by formula (II) is (1-10): (1-10): 1; and / or In S2, the volume molar ratio of the organic solvent a to the compound represented by formula (II) is (0.2-2) mL:1 mmoL; and / or In S2, the reaction temperature is (20-40)°C; and / or In S2, the organic solvent a is at least one of N,N-dimethylformamide, dimethyl sulfoxide or toluene; and / or In S2, the organic base is at least one of imidazole, pyridine or triethylamine; and / or In S2, the TBS hydroxyl protecting agent is tert-butyldimethylsilyl chloride or tert-butyldimethylsilyl trifluoromethanesulfonate.

7. The method for preparing the small molecule acid pyrazole curcumin derivatives according to claim 4, characterized in that: In S3, the molar ratio of the small molecule acid compound, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole and the compound represented by formula (III) is (1-10):(1-10):(1-10):1; and / or In S3, the organic solvent b is at least one of anhydrous dichloromethane, N,N-dimethylformamide or dimethyl sulfoxide; and / or In S3, the volume molar ratio of the organic solvent b to the compound represented by formula (III) is (5-50) mL:1 mmoL; and / or In S3, the temperature of the acid-amine condensation reaction is (20-40)°C.

8. The method for preparing the small molecule acid pyrazole curcumin derivatives as claimed in claim 4, characterized in that: In S4, the volume molar ratio of the glacial acetic acid, the fluoride and the compound represented by formula (IV) is (0.02-0.2) mL: (0.5-5) mL: 1 mmoL; and / or In S4, the organic solvent c is anhydrous tetrahydrofuran; and / or In S4, the fluoride is one or both of tetrabutylammonium fluoride and pyridine hydrogen fluoride complex; and / or In S4, the volume molar ratio of the organic solvent c to the compound represented by formula (IV) is (10-50) mL:1 mmoL; and / or In S4, the temperature of the deprotection reaction is (-10 to 10)°C.

9. Use of the small molecule acid pyrazole curcumin derivatives according to claim 1 or 2 in the preparation of anti-lung cancer drugs.

Citation Information

Patent Citations

  • Curcumin substituted pyrazole derivatives, and preparation method and uses thereof

    CN101570512A

  • Curcumin-amino acid methyl ester derivative as well as preparation method and application thereof

    CN117946007A